Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

Halozyme Therapeutics has stopped its pivotal phase 3 study investigating its lead pancreatic cancer drug – and has announced a major restructuring of its workforce that has resulted in a 55% reduction ... In  2015, AbbVie paid Halozyme nearly $1.2bn

Latest news

  • Halozyme to resume pancreatic cancer study Halozyme to resume pancreatic cancer study

    FDA says PEGPH20 trial can continue. There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to

  • Halozyme halts pancreatic cancer trial Halozyme halts pancreatic cancer trial

    The biopharma company is investigating PEGPH20’s links to blood clot. Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the ... As for the fate of PEGPH20, Halozyme's CEO Dr Helen Torley

  • Baxter re-files HyQvia for immunodeficiency in US Baxter re-files HyQvia for immunodeficiency in US

    HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for

  • Roche wins EU approval for injectable Herceptin Roche wins EU approval for injectable Herceptin

    Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.

  • Drug delivery

    Halozyme receives $9m upfront and up to $54m in development and regulatory milestones. ... Commercialisation. 134. Halozyme Therapeutics/Intrexon Corp. rHuPH20 enzyme drug delivery. technology for COPD and genetic emphysema.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products

  • Pharma deals during December 2014 Pharma deals during December 2014

    Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Quick links

Infographics

Multimedia